{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/alopecia-androgenetic-male/management/management/","result":{"pageContext":{"chapter":{"id":"18247780-bdd9-5da4-9d33-1bcf2a883881","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 197df380-2b2e-4aed-93fc-9ace15043936 --><h2>Scenario: Management</h2><!-- end field 197df380-2b2e-4aed-93fc-9ace15043936 -->","summary":"Covers the management of men with androgenetic alopecia.","htmlStringContent":"<!-- begin item fda9b6aa-b21a-43ab-ba25-af8c732a3246 --><!-- begin field b4ce352b-9c22-424e-a2e4-acbc01592ffc --><p>From age 18 years onwards (Male).</p><!-- end field b4ce352b-9c22-424e-a2e4-acbc01592ffc --><!-- end item fda9b6aa-b21a-43ab-ba25-af8c732a3246 -->","topic":{"id":"5f58d6a9-7ba5-59ad-b7d6-e461768e2621","topicId":"c4dc3303-ee1d-42aa-8da5-078adb684e06","topicName":"Alopecia, androgenetic - male","slug":"alopecia-androgenetic-male","lastRevised":"Last revised in July 2018","chapters":[{"id":"e3fc5b8b-475e-5a1f-a596-104fbf00064f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"c40b9d81-bd18-5ef2-8284-4c4e6005d65c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d860e13e-49f1-54f2-872f-2f3439f27003","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"bbc072f8-3fd9-5a1c-b94c-a0e4fd6edc2f","slug":"changes","fullItemName":"Changes"},{"id":"746928be-2acf-5ae9-9f81-02a942d56a15","slug":"update","fullItemName":"Update"}]},{"id":"3f6cf011-8136-5f24-8cce-31a439cce866","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5e802365-89ef-5f47-a758-6c880bb456ac","slug":"goals","fullItemName":"Goals"},{"id":"9ed869e3-e3ae-56e1-ae20-0a46d6e20fa2","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d90f156b-7429-5580-b4c3-e50d840d1c8a","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c879d8ad-590c-56af-9685-9eb9a2e30d54","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9e4f37dc-4cc8-5e88-a803-5ca32ca17da9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5df134be-2105-5321-86a8-71ed6dca8ebb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"8a3725c2-b01f-5dd8-a319-33387b40d0ee","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"762358f6-f003-57e8-97ff-1c81299e9364","slug":"definition","fullItemName":"Definition"},{"id":"9ee0c90d-fd96-523f-8f6f-7a26ec56b9c7","slug":"prognosis","fullItemName":"Prognosis"},{"id":"55784b07-7a42-5c0b-9ff3-e9c83216cb1e","slug":"complications","fullItemName":"Complications"},{"id":"7cde82a5-0086-5e04-a669-ec49787685f0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"33fac4d7-a95d-526c-936a-6983e3a12d95","slug":"causes","fullItemName":"Causes"},{"id":"84f86e20-aa91-5e2b-b0b6-bb3cfbf655d6","slug":"risk-factors","fullItemName":"Risk factors"}]},{"id":"4b1bf49e-974e-517b-abd6-59b7ea701502","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"486adc7a-b20b-584e-b20c-1408c8f2dc42","slug":"diagnosis-assessment","fullItemName":"Diagnosis and assessment"},{"id":"afbd97db-7525-51a6-aafe-6e937f1cc3e1","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"4fa73515-d20e-5178-9d6b-eebf5ae2d527","slug":"investigations","fullItemName":"Investigations"}]},{"id":"622bcbbb-d3de-5b15-9b55-ddc4eff327ab","fullItemName":"Management","slug":"management","subChapters":[{"id":"18247780-bdd9-5da4-9d33-1bcf2a883881","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"37e93d68-3a6a-5889-a376-afa236d390aa","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"baab0697-37a1-5edf-88ac-cfb6e2e5656b","slug":"topical-minoxidil-2percent-5percent","fullItemName":"Topical minoxidil 2% and 5%"},{"id":"c42ae7ac-8352-5cac-874c-69c24b99081b","slug":"finasteride","fullItemName":"Finasteride"}]},{"id":"b22c3dba-eb5b-5afa-8f70-43908da7e430","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"444a2a47-2816-5baa-928f-c2bc1b56af85","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1d1c173f-70b1-5d42-916a-a0bcb5c3557c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"531d7be1-4263-5fd6-a49b-a920a3aaca95","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"dede1c7c-59ec-550c-be37-91849715881e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ddffa446-a263-56e2-a985-c07fa5d06760","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3b6f4b5d-c7dd-5142-a6e8-2741d9019ade","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0b9ed9ca-1edc-5d61-938a-a6abc5daa77a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"622bcbbb-d3de-5b15-9b55-ddc4eff327ab","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"ee47eb9a-f463-55a3-8ce6-ce0aa8c9f805","slug":"management-in-primary-care","fullItemName":"Management in primary care","depth":3,"htmlHeader":"<!-- begin field 6b2cb4de-1e6e-4e37-940a-05e2a6dc6944 --><h3>How should I manage a man with androgenetic alopecia?</h3><!-- end field 6b2cb4de-1e6e-4e37-940a-05e2a6dc6944 -->","summary":null,"htmlStringContent":"<!-- begin item c3fb9735-d7c8-4b6d-8ad4-53a2f13a0e94 --><!-- begin field ec9fddcd-9b0a-4320-b80b-4e1bddbf3e2d --><ul><li><strong>Explain the natural course of the condition, what the man may expect in terms of continuing hair thinning, and long term <a class=\"topic-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/background-information/prognosis/\">prognosis</a>. Advise that:</strong><ul><li>Hair may be shampooed as frequently as desired without fear of worsening hair loss.</li><li>Drug treatments may help to prevent progression of hair loss, and this may be difficult to detect.</li></ul></li><li><strong>Offer drug treatment and/or <a class=\"topic-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/management/management/#aesthetic-options\">aesthetic options</a> depending on the person's preference.</strong><ul><li><strong>No treatment</strong> is an option in mild androgenetic alopecia and the use of aesthetic options may be a suitable alternative.</li><li><strong>For drug treatment, consider topical minoxidil or oral finasteride </strong>— neither are available on the NHS and both are expensive. There are three options: <ul><li>Twice daily application of 1mL of minoxidil 2% solution — available over-the-counter or on a private prescription.</li><li>Twice daily application of 1 mL minoxidil 5% solution (may be slightly more effective than the 2% strength, but carries a higher risk of scalp irritation) — available over-the-counter or on private prescription.</li><li>Oral finasteride 1 mg daily — available on private prescription only.</li></ul></li></ul></li><li><strong>Explain the following if a man is considering treatment with topical minoxidil or oral finasteride:</strong><ul><li>Clinical results with either treatment may be minimal. Both drug treatments work better if used early in the natural history of hair loss development, and are much less effective when alopecia is established.</li><li>Hair regrowth is not usually noticed for at least 4–6 months and stopping treatment will lead to a loss of any benefit within 6–12 months, sometimes with a period of rebound shedding.</li><li>Either treatment needs to be taken indefinitely to maintain any effect.</li><li>Both medications are costly options in the long term.</li><li>Both share good safety profiles but have different adverse effects.<ul><li><div>If the man prefers a topical treatment, a reasonable approach would be to initiate minoxidil 2%, and, if this is tolerated, switch to minoxidil 5% to maximize the effect.</div></li><li>For further information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/prescribing-information/\">Prescribing information</a>.</li></ul></li></ul></li><li><strong>If the man starts drug treatment, assess the response at 6 months. </strong><ul><li>If successful, continue treatment indefinitely. </li><li>If there is no response after 1 year, discontinue treatment and consider <a class=\"topic-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/management/management/#referral\">referral</a> to a dermatologist, depending on clinical judgement and the man's wishes.</li></ul></li><li><strong>Manage any psychological or <a class=\"topic-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/background-information/complications/\">psychosocial complications</a> appropriately.</strong><ul><li>Local support groups or counselling may be helpful if the man requires further support, such as Alopecia UK (<a href=\"http://www.alopeciaonline.org.uk/index.asp\" data-hyperlink-id=\"fd3fcd6d-889c-42ea-b610-a93100b40bf9\">www.alopeciaonline.org.uk</a>).</li></ul></li><li><strong>Offer the patient information leaflet</strong> <a href=\"http://www.bad.org.uk/shared/get-file.ashx?id=3831&itemtype=document\" data-hyperlink-id=\"adae0c87-37c0-4fb0-9b79-a93100b41258\">Male Pattern Hair Loss</a> (Androgenetic Alopecia) which is available on the British Association of Dermatologists (BAD) website available at <a href=\"http://www.bad.org.uk/\" data-hyperlink-id=\"0cda7e85-2cf5-4321-b9b9-a93100b41279\">www.bad.org.uk</a>.</li></ul><!-- end field ec9fddcd-9b0a-4320-b80b-4e1bddbf3e2d --><!-- end item c3fb9735-d7c8-4b6d-8ad4-53a2f13a0e94 -->","subChapters":[{"id":"25944272-5006-59c0-a506-4af87e42a228","slug":"aesthetic-options","fullItemName":"Aesthetic options","depth":4,"htmlHeader":"<!-- begin field f077cfb9-bc5c-403d-9830-565b45452896 --><h4>Aesthetic options</h4><!-- end field f077cfb9-bc5c-403d-9830-565b45452896 -->","summary":null,"htmlStringContent":"<!-- begin item 32603706-c760-4629-9a30-80dfeec042c6 --><!-- begin field 721b41b5-5574-45bc-99cc-cdfc789318df --><ul><li><strong>Hairpieces and wigs </strong>— these can be interwoven (these are more expensive and need regular readjustment) or worn on top of the man's own hair. <ul><li>In certain circumstances, men on low incomes may be eligible for free or reduced cost wigs on the NHS if an independent funding request is accepted.</li><li>Be aware that in order to obtain an NHS prescription for a wig, referral to a dermatologist may be required. More information on buying wigs and NHS policy is available at <a data-hyperlink-id=\"743f5e52-db52-4479-a715-a931009f14dc\" href=\"http://www.nhs.uk/NHSEngland/Healthcosts/Pages/Wigsandfabricsupports.aspx\" target=\"_blank\">NHS</a>.</li><li>Further information on synthetic wigs and human hair wigs, including advice on choosing the right wig and how to care for it, is available on the <a data-hyperlink-id=\"b2c2e46a-3819-4b81-a66a-a931009f15cc\" href=\"http://www.alopeciaonline.org.uk/\" target=\"_blank\">Alopecia UK website</a>.</li></ul></li><li><strong>Cosmetic options</strong> to camouflage hair loss are not available on the NHS. They include:<ul><li>Hairstyling — waving, dyeing, sprays, and mousses.</li><li>Hair camouflage — such as a keratin microfibre product which may provide scalp cover.</li><li>Hair extensions — provide fullness but may result in further pulling and traction on existing follicles.</li></ul></li><li><strong>Surgical hair transplantation</strong> for androgenetic alopecia is not available on the NHS and the cost may be prohibitive.<ul><li>Modern techniques use follicular unit transplantation to produce a more natural appearance than older techniques such as punch grafts, micro-grafts, slit grafts, and strip grafts.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Avram and Rogers, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Blumeyer et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">BMJ, 2015</a>]</p><!-- end field 721b41b5-5574-45bc-99cc-cdfc789318df --><!-- end item 32603706-c760-4629-9a30-80dfeec042c6 -->","subChapters":[]},{"id":"2a8c9ba1-23fc-594f-88d3-aea09bb14fd3","slug":"basis-for-recommendation-98d","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 55d043d1-ef0b-4d5c-8413-b8802a45da58 --><h4>Basis for recommendation</h4><!-- end field 55d043d1-ef0b-4d5c-8413-b8802a45da58 -->","summary":null,"htmlStringContent":"<!-- begin item 98d62c46-ad4c-4975-9aca-1b4fa2202caa --><!-- begin field f58da67f-324f-463c-bf9d-2fb28dbe0495 --><p>The recommendations on the management of androgenetic alopecia in men are based on expert opinion in a European consensus guideline for the treatment of androgenetic alopecia in women and men [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Blumeyer et al, 2011</a>], a dermatological guideline on the use of finasteride in androgenetic alopecia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Mysore and Shashikumar, 2016</a>], a systematic review and meta-analysis on the efficacy of topical minoxidil in androgenetic alopecia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Gupta and Charrette, 2015</a>], expert opinion in review articles on androgenetic alopecia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Mapar and Omidian, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Avram and Rogers, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Shamsaldeen et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Piraccini and Alessandrini, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Varothai and Bergfeld, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Irwig, 2015</a>], the British Medical Journal (BMJ) Best practice review article on androgenetic alopecia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">BMJ, 2015</a>], and information in the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">BNF 71, 2016</a>].</p><h5><strong>The option of no treatment</strong></h5><ul><li>Expert opinion recommends that, for the vast majority of men, the option of no treatment is most appropriate which avoids financial costs and possible adverse effects from drug treatments. Aesthetic options such as hairpieces, hair extensions, or hair styling may cover the scalp or help to camouflage the hair loss [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Blumeyer et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">BMJ, 2015</a>].</li></ul><h5>Topical minoxidil 2% and 5%</h5><ul><li>Minoxidil is a potassium-channel opener and potent vasodilator, but its mechanism of action for hair regrowth remains unclear. It is thought to increase the anagen phase of hair growth and reverse the minaturization of hair follicles through angiogenic effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Blumeyer et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Shamsaldeen et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">BMJ, 2015</a>].</li><li>There is evidence that topical minoxidil 2% and 5% strengths promote hair growth in several randomized controlled trials, systematic reviews, and meta-analyses [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Olsen et al, 2002</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Blumeyer et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Gupta and Charrette, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Varothai and Bergfeld, 2014</a>].<ul><li>One systematic review showed that topical minoxidil is more effective than placebo in promoting total and non-vellus hair growth. A significantly higher proportion of participants in the minoxidil group had greater hair growth than participants in the placebo group according to both investigator assessment and patient self-assessment (relative risk [RR], 2.28; 95% CI, 1.58-3.31 and RR, 1.56; 95% CI, 1.34-1.80) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Gupta and Charrette, 2015</a>].</li><li>One randomized controlled trial (n = 393) of men aged 18–49 years with androgenetic alopecia compared the application of topical minoxidil 2% solution twice daily with topical minoxidil 5% solution twice daily and placebo. After 48 weeks of treatment, 5% topical minoxidil was significantly superior to the 2% preparation and placebo in terms of change from baseline in non-vellus hair count, patient rating of scalp coverage and treatment benefit, and investigator rating of scalp coverage. Hair count data indicated that response to treatment occurred earlier with the 5% compared with the 2% strength. However, an increased occurrence of itch and local irritation was observed with the 5% preparation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Olsen et al, 2002</a>].</li></ul></li><li>The best responders to topical minoxidil are thought to be those in whom the balding process is early and not severe [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Mapar and Omidian, 2007</a>].</li><li><div>CKS could not find any guidance in the literature on which strength of minoxidil to initiate. Expert opinion from some previous external reviewers of this CKS topic recommended starting with minoxidil 2% and then increasing to the 5% strength to minimize adverse effects. Others recommended starting treatment with minoxidil 5% and reducing to the 2% strength if irritation occurs. </div></li><li>The recommendation to start a trial of topical minoxidil for 6–12 months is based on expert opinion in a best practice review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">BMJ, 2015</a>]. </li></ul><h5>Oral finasteride</h5><ul><li>The use of oral finasteride in men is based on good-quality evidence from large randomized controlled trials (RCTs), which demonstrate that hair growth peaks at about 1 year after starting treatment, and although there is a slight decline thereafter, measures of hair density stay above baseline values [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Blumeyer et al, 2011</a>].<ul><li>One multi-centre, double-blind RCT (n = 424) compared finasteride 1 mg with placebo in men aged 41–60 years with androgenetic alopecia. At 24 months, 39% of the finasteride group had improved hair regrowth compared with 4% in the placebo group according to photographic assessments and patient-self assessments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Whiting et al, 2003</a>].</li><li>Another multi-centre, double-blind RCT (n = 414) compared finasteride 1 mg, finasteride 0.2mg, and placebo in men aged 20–50 years with androgenetic alopecia. At 48 weeks, 58% of the finasteride 1 mg group, 54% of the finasteride 0.2 mg group and 6% of the placebo group improved according to photographic assessments and patient-self assessment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Kawashima et al, 2004</a>].</li><li>The response to treatment should be assessed at 6 months, although in some men it may not become evident until 12 months [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Blumeyer et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">BMJ, 2015</a>].</li></ul></li></ul><h5>Choice of drug treatment</h5><ul><li>There is insufficient evidence to determine the relative efficacy of oral finasteride compared with topical minoxidil. CKS did not identify any RCTs that have studied this comparison, and existing comparative studies of the two treatments provide conflicting results [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Blumeyer et al, 2011</a>].</li></ul><h5>Combining medical treatments</h5><ul><li>CKS does not recommend combination treatment with topical minoxidil and oral finasteride as there is insufficient evidence for this.</li></ul><h5>Aesthetic options</h5><ul><li>The information on aesthetic options is based on expert opinion in the European consensus guideline for the treatment of androgenetic alopecia in women and men [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Blumeyer et al, 2011</a>], expert opinion in a review article on androgenetic alopecia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Avram and Rogers, 2009</a>], and the British Medical Journal (BMJ) Best practice review article on androgenetic alopecia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">BMJ, 2015</a>].<ul><li>Unless used as part of reconstructive surgery, hair transplantation is considered as cosmetic surgery and is not funded by the NHS, but may be available by private referral. It is therefore important to consider both the risk and price of surgical hair treatments. Many people cannot afford this type of elective surgery.</li></ul></li></ul><!-- end field f58da67f-324f-463c-bf9d-2fb28dbe0495 --><!-- end item 98d62c46-ad4c-4975-9aca-1b4fa2202caa -->","subChapters":[]}]},{"id":"44962d36-8233-5064-ba98-0dd6d8373613","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field a97f28ab-a696-4f8e-85cb-abb4beeb623e --><h3>When should I refer a man with androgenetic alopecia?</h3><!-- end field a97f28ab-a696-4f8e-85cb-abb4beeb623e -->","summary":null,"htmlStringContent":"<!-- begin item cbdbadf0-8196-4909-a07a-a92ac13028e0 --><!-- begin field 8d7fe072-a2c0-4904-ae75-04e410216846 --><ul><li>Referral to a dermatologist is not usually necessary for typical androgenetic alopecia.</li><li>Consider referral to the appropriate specialist if a man has:<ul><li>An atypical presentation, extensive hair loss, or an uncertain diagnosis — refer to a dermatologist with a special interest in hair, if available.</li><li>A possible <a class=\"topic-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/diagnosis/differential-diagnosis/\">underlying condition</a> requiring treatment in secondary care — refer for further investigation depending on clinical judgement.<strong> </strong></li><li>No response to treatments available in primary care — refer to a dermatologist for consideration of specialist treatments such as anti-hormonal agents. </li><li>Adverse <a class=\"topic-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/background-information/complications/\">psychosocial effects</a> — referral to psychological services may be helpful.</li></ul></li></ul><!-- end field 8d7fe072-a2c0-4904-ae75-04e410216846 --><!-- end item cbdbadf0-8196-4909-a07a-a92ac13028e0 -->","subChapters":[{"id":"b23dead7-b06f-50f2-8053-9871d87bd9e3","slug":"basis-for-recommendation-3dc","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 6a1453db-7437-465f-98a9-afeaccbe7592 --><h4>Basis for recommendation</h4><!-- end field 6a1453db-7437-465f-98a9-afeaccbe7592 -->","summary":null,"htmlStringContent":"<!-- begin item 3dc69913-cee3-4eae-a431-3839ed9c0cd2 --><!-- begin field d0790cf0-3002-4fa3-b6cd-05a7f9cca571 --><p>The recommendations on referral are extrapolated from expert opinion in a European consensus guidelines on the diagnosis and management of androgenetic alopecia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Blume-Peytavi et al, 2010</a>], expert opinion in review articles on androgenetic alopecia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Piraccini and Alessandrini, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Varothai and Bergfeld, 2014</a>], and the British Medical Journal (BMJ) Best practice article on androgenetic alopecia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">BMJ, 2015</a>].</p><h5>Secondary care management</h5><ul><li>More advanced specialist tools for assessment may be available, such as the trichogram (microscopic examination of hair roots), photographic techniques, and dermatoscopy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Piraccini and Alessandrini, 2014</a>].</li><li>Secondary care treatment options may include oral and topical anti-hormonal agents such as anti-androgens, or surgical treatments such as follicular unit hair transplantation (not available on the NHS) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Varothai and Bergfeld, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">BMJ, 2015</a>].</li></ul><!-- end field d0790cf0-3002-4fa3-b6cd-05a7f9cca571 --><!-- end item 3dc69913-cee3-4eae-a431-3839ed9c0cd2 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}